loading
Precedente Chiudi:
$3.29
Aprire:
$3.88
Volume 24 ore:
4.32M
Relative Volume:
10.49
Capitalizzazione di mercato:
$84.81M
Reddito:
-
Utile/perdita netta:
$-45.08M
Rapporto P/E:
-3.3151
EPS:
-0.73
Flusso di cassa netto:
$-33.68M
1 W Prestazione:
+76.64%
1M Prestazione:
+87.60%
6M Prestazione:
+132.69%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$1.85
$3.9035
Intervallo di 1 settimana:
Value
$1.38
$3.9035
Portata 52W:
Value
$0.726
$3.9035

Galectin Therapeutics Inc Stock (GALT) Company Profile

Name
Nome
Galectin Therapeutics Inc
Name
Telefono
678-620-3186
Name
Indirizzo
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Name
Dipendente
15
Name
Cinguettio
@galectingalt
Name
Prossima data di guadagno
2025-03-31
Name
Ultimi documenti SEC
Name
GALT's Discussions on Twitter

Confronta GALT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
GALT
Galectin Therapeutics Inc
2.42 84.81M 0 -45.08M -33.68M -0.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.87 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
509.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
309.70 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.08 28.51B 3.81B -644.79M -669.77M -6.24

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-08-13 Reiterato H.C. Wainwright Buy
2019-02-13 Iniziato B. Riley FBR Buy
2017-12-07 Reiterato H.C. Wainwright Buy
2017-11-28 Reiterato H.C. Wainwright Buy
2017-10-19 Iniziato ROTH Capital Buy
2017-03-30 Aggiornamento H.C. Wainwright Neutral → Buy
2016-10-03 Downgrade FBR & Co. Outperform → Mkt Perform
2016-09-29 Downgrade H.C. Wainwright Buy → Neutral
2016-09-28 Downgrade ROTH Capital Buy → Sell
2016-03-28 Ripresa H.C. Wainwright Buy
2015-09-21 Iniziato H.C. Wainwright Buy
2014-08-01 Downgrade Aegis Capital Buy → Hold
2014-07-30 Reiterato MLV & Co Buy
2014-07-29 Reiterato MLV & Co Buy
2014-04-02 Reiterato MLV & Co Buy
2014-02-10 Reiterato Aegis Capital Buy
2014-01-09 Reiterato Aegis Capital Buy
2013-12-03 Iniziato MLV & Co Buy
2013-08-19 Reiterato Aegis Capital Buy
Mostra tutto

Galectin Therapeutics Inc Borsa (GALT) Ultime notizie

pulisher
Jun 18, 2025

Galectin Therapeutics (NASDAQ:GALT) Now Covered by Analysts at HC Wainwright - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Galectin Therapeutics stock rating initiated at buy by H.C. Wainwright - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Analyst Forecast For Galectin Therapeutics Inc (NASDAQ: GALT) - Stocksregister

Jun 17, 2025
pulisher
Jun 17, 2025

Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainw - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

HC Wainwright Initiates Coverage on Galectin Therapeutics (NASDAQ:GALT) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

HC Wainwright & Co. Initiates Coverage with Buy Rating on GALT | - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainwright | GALT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

Transcript : Galectin Therapeutics Inc.Special Call - MarketScreener

Jun 16, 2025
pulisher
Jun 10, 2025

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belap - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Galectin Therapeutics to Host Virtual Key Opinion Leader Event on MASH Cirrhosis and Portal Hypertension Treatment - Nasdaq

Jun 10, 2025
pulisher
Jun 10, 2025

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension - Yahoo Finance

Jun 10, 2025
pulisher
Jun 09, 2025

MASH Market Size in the 7MM was ~USD 1.8 billion in 2023, is projected to grow at a CAGR of 24%, estimates DelveInsight - The Globe and Mail

Jun 09, 2025
pulisher
Jun 02, 2025

Northern Trust Corp Purchases 9,994 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Jun 02, 2025
pulisher
May 26, 2025

Galectin Therapeutics Inc (NASDAQ: GALT) Stock: Investors Need To Know This - Stocksregister

May 26, 2025
pulisher
May 26, 2025

Portal Hypertension Market Growth Projections 2023-2032: - openPR.com

May 26, 2025
pulisher
May 20, 2025

MASH Market Report 2034: Statistics, Revenue, Patient Pool, EMA, PDMA, FDA Approvals, Clinical Trials, Medication, MOA, ROA and Companies by DelveInsight - The Globe and Mail

May 20, 2025
pulisher
May 20, 2025

Galectin Therapeutics (GALT) to Release Earnings on Thursday - MarketBeat

May 20, 2025
pulisher
May 15, 2025

Galectin Therapeutics (GALT) Advances in Belapectin Analysis | G - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Galectin Therapeutics (GALT) Advances in Belapectin Analysis | GALT Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Galectin Therapeutics Reports Q1 2025 Financial Results and Business Update - TradingView

May 15, 2025
pulisher
May 15, 2025

GALECTIN THERAPEUTICS INC SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 15, 2025

Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Barclays PLC Purchases 26,047 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

May 15, 2025
pulisher
May 14, 2025

Galectin Therapeutics (GALT) Projected to Post Quarterly Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options | DelveInsight - PR Newswire UK

May 13, 2025
pulisher
May 12, 2025

Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com Canada

May 12, 2025
pulisher
May 12, 2025

Galectin Therapeutics Presents NAVIGATE Study Data Of Belapectin At EASL 2025 Congress - Nasdaq

May 12, 2025
pulisher
May 12, 2025

Galectin Therapeutics (GALT) Reveals Promising NAVIGATE Study Re - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Belapectin shows promise in MASH cirrhosis trial - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

Galectin Therapeutics Updates Corporate Presentation on Belapectin - TipRanks

May 12, 2025
pulisher
May 12, 2025

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - The Manila Times

May 12, 2025
pulisher
May 12, 2025

Galectin Therapeutics Inc. Reports Positive NAVIGATE Trial Results for Belapectin in MASH Cirrhosis Treatment - Nasdaq

May 12, 2025
pulisher
May 07, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Position Boosted by JPMorgan Chase & Co. - Defense World

May 07, 2025
pulisher
May 02, 2025

Renaissance Technologies LLC Decreases Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - The AM Reporter

May 02, 2025
pulisher
May 01, 2025

9 Short Squeeze Stocks That Could Take Off - US News Money

May 01, 2025
pulisher
May 01, 2025

Geode Capital Management LLC Has $1.12 Million Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

May 01, 2025
pulisher
Apr 30, 2025

LPL Financial LLC Has $179,000 Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Apr 30, 2025
pulisher
Apr 29, 2025

RBC Capital Keeps Their Buy Rating on Brookfield Infrastructure (BIP) - The Globe and Mail

Apr 29, 2025
pulisher
Apr 25, 2025

Will Alphabet Stock Keep Rising After Crushing Q1 Earnings Expectations? - The Globe and Mail

Apr 25, 2025
pulisher
Apr 22, 2025

CEO.CA's Inside the Boardroom: Yukon Metals CEO Breaks Down Upcoming Drilling Plans for Star River Gold-Silver and AZ Copper Targets - The Globe and Mail

Apr 22, 2025
pulisher
Apr 16, 2025

MASH Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Patient Pool, MOA, ROA and Companies by DelveInsight - The Globe and Mail

Apr 16, 2025
pulisher
Apr 16, 2025

Commonwealth Equity Services LLC Reduces Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat

Apr 16, 2025
pulisher
Apr 15, 2025

Game-Changing MASH Cirrhosis Treatment Results: New Clinical Data Shows Promise in Portal Hypertension - Stock Titan

Apr 15, 2025
pulisher
Apr 11, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLC - Defense World

Apr 11, 2025
pulisher
Apr 11, 2025

HC Wainwright Analysts Boost Earnings Estimates for GALT - MarketBeat

Apr 11, 2025
pulisher
Apr 09, 2025

FY2029 Earnings Forecast for GALT Issued By HC Wainwright - MarketBeat

Apr 09, 2025
pulisher
Apr 08, 2025

Psoriasis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Apr 08, 2025
pulisher
Apr 07, 2025

Galectin Therapeutics (NASDAQ:GALT) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Apr 07, 2025

Galectin Therapeutics Inc Azioni (GALT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Galectin Therapeutics Inc Azioni (GALT) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Shlevin Harold H.
Director
Dec 30 '24
Buy
1.16
6,500
7,540
15,206
Jamil Khurram
Chief Medical Officer
Dec 23 '24
Option Exercise
0.00
40,000
0
40,000
Jamil Khurram
Chief Medical Officer
Dec 23 '24
Sale
0.88
13,654
12,044
26,346
LEWIS JOEL
President and CEO
Dec 23 '24
Option Exercise
0.00
56,000
0
953,012
LEWIS JOEL
President and CEO
Dec 23 '24
Sale
0.89
56,000
49,610
897,012
CALLICUTT JACK W
Chief Financial Officer
Dec 23 '24
Option Exercise
0.00
40,000
0
47,614
CALLICUTT JACK W
Chief Financial Officer
Dec 23 '24
Sale
0.89
40,000
35,492
7,614
Zordani Richard A. Jr.
Director
Dec 24 '24
Buy
0.82
10,000
8,164
42,083
ELDRED KARY
Director
Dec 24 '24
Buy
0.82
13,469
11,045
63,682
FREEMAN KEVIN D
Director
Dec 24 '24
Buy
0.81
10,000
8,134
44,769
$21.16
price down icon 1.86%
$34.86
price down icon 0.14%
$20.56
price up icon 1.98%
$102.68
price up icon 3.24%
$106.53
price up icon 2.04%
biotechnology ONC
$247.08
price down icon 2.25%
Capitalizzazione:     |  Volume (24 ore):